Weiss Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Weiss Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,596	Closed	-$411K	–	611
2025 Q3	$411K	Buy	+7,596	New	+$434K	﹤0.01%	475
2025 Q2	–	Sell	-7,394	Closed	-$523K	–	424
2025 Q1	$523K	Buy	+7,394	New	+$497K	0.01%	227
2024 Q2	–	Sell	-4,947	Closed	-$432K	–	301
2024 Q1	$432K	Sell	4,947 -12,902	-72%	-$1.16M	0.01%	223
2023 Q4	$1.72M	Buy	+17,849	New	+$1.58M	0.08%	121

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Weiss Asset Management's BMRN Position: Q4 2025 in Review

Weiss Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 7,596 shares — an estimated $411K sold.

Weiss Asset Management first reported a position in BMRN in Q4 2023 and held it in 4 quarters. The position peaked at $1.72M in Q4 2023. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Weiss Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Weiss Asset Management sold 7,596 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $411K.
Weiss Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 4 quarters.
Weiss Asset Management's BioMarin Pharmaceuticals position peaked at $1.72M in Q4 2023.
540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Weiss Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.